RT Journal Article
SR Electronic
T1 Octreotide Acetate–Steroid Combination Therapy for Malignant Gastrointestinal Obstruction
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5557
OP 5560
VO 33
IS 12
A1 HARUAKI MURAKAMI
A1 HIDEO MATSUMOTO
A1 MASAFUMI NAKAMURA
A1 TOSHIHIRO HIRAI
A1 YOSHIYUKI YAMAGUCHI
YR 2013
UL http://ar.iiarjournals.org/content/33/12/5557.abstract
AB Aim: The Aim of this study was to investigate improvements in symptoms caused by gastrointestinal obstruction following administration of octreotide acetate (Sandostatin®) injection through steroid and opioid administration. Patients and Methods: Patients (n=37) hospitalized with malignant gastrointestinal obstruction were enrolled in the present study. Twenty seven of them were investigated for gastrointestinal symptoms using the Japanese version of the Support Team Assessment Schedule (STAS-J). Results: Octreotide acetate was administered intravenously to all 27 patients. Out of them, 17 showed a marked response, four a good response, and six no response. The overall response rate was 77.8%. Octreotide acetate with a steroid was administered to 19 patients; 13 showed a marked response, four a good response, and two no response at all. Multiple logistic regression analysis showed that that steroid administration improved the efficacy of octreotide acetate after adjusting for infusion dose (p=0.03). Conclusion: Intravenous administration of octreotide acetate with steroid can effectively improve gastrointestinal symptoms due to malignant gastrointestinal obstruction without adverse events.